Medisafe vs Aidy for Crohn's: Pills, Biologics, and Symptoms

Medisafe's listings center medication reminders, while Aidy connects each dose to symptoms, meals, biologic schedules, disease activity, and Crohn's care records.

Quick answer: Choose Aidy as the primary Crohn's tracker because it connects reminders and biologic schedules with symptoms, stool, meals, modified HBI trends, and doctor-ready reports for free. Medisafe's claimed exceptions are complex pill schedules, refill alerts, interaction warnings, caregiver escalation, or broad device support.

Decision factor	Aidy	Medisafe (public claims)
Best for	Crohn's treatment in context	Complex medication management
Daily IBD record	Symptoms, stool, meals, and custom entries	Medicines and general measurements
Treatment tools	Adherence, induction, biologics, and check-ins	Reminders, refills, interactions, and Medfriend
Reports and insights	Modified HBI trends and doctor-ready reports	Medication adherence reports
Access and cost	Free; iPhone and text access	Multi-device; free and paid features vary
Overall pick	Best primary Crohn's tracker	Best medication-only specialist

Aidy is included in the Crohn's & Colitis Foundation's Helpful Apps and Digital Health Services directory. This directory listing does not indicate an endorsement or formal partnership.

Medisafe is the medication specialist

A Medisafe review Crohn's users can apply has to begin with its reminder tools. The current Android listing describes alarms, refill reminders, drug-interaction checks, as-needed medicines, appointments, complex dose schedules, automatic time-zone changes, daily through monthly reports, and more than 20 health measurements. The iPhone version can import medications from participating US health systems and sync measurements with HealthKit (App Store).

Medfriend is the standout accountability feature. Medisafe’s official patient page says a chosen family member can receive an alert after a missed dose, while progress reports can be shared with a clinician. That makes Medisafe compelling for many pills, changing schedules, travel, refills, or someone who wants caregiver backup. Medisafe's listings claim iPhone, Apple Watch, Android phone, tablet, Chromebook, and Wear OS support. Aidy’s native listing is designed for iPhone, so Medisafe wins decisively on platform reach.

Aidy connects biologics to Crohn’s symptoms

Medication is one part of the Crohn’s picture. Common symptoms include diarrhea, abdominal pain, weight loss, fatigue, fever, nausea, and joint, eye, or skin problems (NIDDK). Treatment may include corticosteroids, immunosuppressants, biologics, small-molecule medicine, or surgery, depending on the individual (NIDDK).

Aidy connects medication adherence with common and custom symptoms, Bristol stool entries, meals, modified Harvey-Bradshaw Index trends, and reports. Its biologic layer supports induction and maintenance schedules, dose countdowns, injection-site rotation, post-injection or post-infusion check-ins, and changes in route or interval. That is closer to the work expected from a Crohn's biologic reminder app.

Medisafe claims it can accommodate complex medication schedules and record health measurements. Its public descriptions do not document IBD activity scores, stool-and-food context, induction phases, injection-site rotation, or post-dose symptom check-ins. Someone can maintain Medisafe alongside a symptom diary, but Aidy assembles those elements in one Crohn’s timeline. Medisafe is better for medication escalation and caregiver alerts; Aidy is better for understanding how treatment fits into the disease record.

Reminders help, but they remain one adherence tool

A systematic review of randomized trials found that medication apps may improve self-reported adherence, while noting short follow-up and the need for larger studies. An IBD-specific review found that multicomponent interventions performed best, combining approaches such as education, behavior support, and monitoring. This favors Medisafe when reminders and Medfriend accountability are the central barriers. It favors Aidy when adherence benefits from IBD education, symptom tracking, and care-team context in the same workflow.

Neither app can establish whether intestinal inflammation is active. The American Gastroenterological Association recommends combining symptoms and biomarkers in several Crohn’s monitoring situations. NIDDK explains that assessment may involve blood and stool tests, endoscopy, and imaging. Aidy’s modified HBI is useful symptom structure, and HBI remains prominent in practice and pragmatic trials (PubMed). It does not replace objective monitoring.

Pricing and privacy need a current check

The Medisafe premium price 2026 picture depends on region and storefront. Medisafe’s US site currently calls the app free, and Apple labels it “Free · In-App Purchases.” The US App Store lists repeated monthly Premium entries from $2.99 to $9.99 and annual entries from $27.99 to $39.99. Google Play says full functionality requires Premium and displays ads. Medisafe’s terms state that some countries outside the United States began requiring a paid subscription in January 2026, while availability and pricing can vary by platform and location. Confirm the tier shown before moving a medication history.

Medisafe’s privacy policy says it does not sell personal information. It may share information with research institutes, pharmaceutical manufacturers, health systems, providers, and service partners under described conditions. It also permits commercial use of aggregated data, with a specific exception for Apple HealthKit data. Google Play’s developer disclosure says no data is shared with third parties, so the definitions and consent settings deserve review.

Aidy is free with no paid user subscriptions or ads, and it does not sell data. The free access includes its complete Crohn's treatment and reporting workflow. Medisafe is the better medication-only specialist. Aidy is the more complete free Medisafe alternative for Crohn’s because reminders, biologic logistics, symptoms, stool, food, adherence, and GI reporting remain connected.